Risk Factors for Patient-Important Upper Gastrointestinal Bleeding
Files
(Published version)
Date
2025
Authors
Deane, A.M.
Lauzier, F.
Adhikari, N.K.J.
Lamontagne, F.
Heels-Ansdell, D.
Thabane, L.
Williamson, D.
Kanji, S.
Barletta, J.F.
Finfer, S.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
American Journal of Respiratory and Critical Care Medicine, 2025; 211(9):1671-1680
Statement of Responsibility
Adam M. Deane, François Lauzier, Neill K. J. Adhikari, François Lamontagne, Diane Heels-Ansdell, Lehana Thabane, David Williamson, Salmaan Kanji, Jeffrey F. Barletta, Simon Finfer, Yaseen Arabi, Marlies Ostermann, John C. Marshall, Nicole L. Zytaruk, Miranda Hardie, Naomi E. Hammond, Gordon Guyatt, Kyle C. White, Karen E. A. Burns, Joanna C. Dionne, Paul J. Young, and Deborah J. Cook, for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group
Conference Name
Abstract
Rationale: Patient-important gastrointestinal bleeding is an endpoint developed by patients and family members; however, risk factors for this outcome are unknown. Objectives: We sought to identify risk factors for patientimportant upper gastrointestinal bleeding among invasively ventilated adults. Methods: This preplanned regression analysis of an international trial database evaluated baseline and time-varying risk factors in the preceding 3 days for patient-important upper gastrointestinal bleeding, accounting for illness severity and the competing risk of death. Measurements and Main Results: Patient-important upper gastrointestinal bleeding occurred in the ICU among 131 of 4,821 (2.7%) patients. Baseline APACHE II score—hazard ratio (HR), 1.24 (95% confidence interval [CI] = 1.12, 1.37) per 5-point increase—and the following were associated with greater risk of patient-important bleeding: inotropes or vasopressors (HR, 2.05 [95% CI = 1.35, 3.12]), severe thrombocytopenia (platelet count, <5 × 10⁹/L) (HR, 2.21 [95% CI = 1.24, 3.94]) and platelet inhibitor drugs (HR, 1.69 [95% CI = 1.11, 2.56]). A lower bleeding risk was associated with pantoprazole (HR, 0.36 [95% CI = 0.25, 0.54]) and enteral nutrition (HR, 0.81 [95% CI = 0.68, 0.97]) for every increase of 500ml/d. There was no interaction between enteral nutrition and pantoprazole (interaction P = 0.94). Allocation to pantoprazole was associated with a lower risk of patient-important upper gastrointestinal bleeding regardless of the volume of enteral nutrition (for 500ml/d: HR, 0.36 [95% CI = 0.22, 0.58]; for no enteral nutrition: HR, 0.36 [95% CI = 0.18, 0.72]). The association of enteral nutrition and bleeding was similar with pantoprazole (HR, 0.82 [95% CI = 0.63, 1.07]) or without pantoprazole (HR, 0.81 [95% CI = 0.66, 1.00]). Conclusions: Several factors are associated with the risk of patient-important upper gastrointestinal bleeding during invasive ventilation.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright © 2025 by the American Thoracic Society. This article is open access and distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/). For reprints, please contact Diane Gern (dgern@thoracic.org).